Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Long-Term Debt
The long-term debt for Labcorp Holdings Inc. (LH) is $5.77 Billion with a year-over-year change of +8.18%. Long-term debt includes bonds, term loans, mortgages, and other borrowings with maturities greater than one year. It represents the company's structural leverage.
LH Long-Term Debt Chart
LH Long-Term Debt
$5.77B+854.04% 20Y
Zoom
Current Long-Term Debt
$5.77B
$5.77 Billion
Year-over-Year Change
+8.18%
vs. $5.33B prior year
Historical Data
30
Years of data available
Annual Long-Term Debt History
| Year | Long-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.77B | +$436.00M | +8.18% |
| 2024 | $5.33B | +$1.28B | +31.48% |
| 2023 | $4.05B | $-984.10M | -19.53% |
| 2022 | $5.04B | $-377.70M | -6.97% |
| 2021 | $5.42B | $-2.50M | -0.05% |
| 2020 | $5.42B | $-370.80M | -6.40% |
| 2019 | $5.79B | $-201.10M | -3.36% |
| 2018 | $5.99B | $-295.90M | -4.71% |
| 2017 | $6.29B | +$1.05B | +20.05% |
| 2016 | $5.24B | $-648.20M | -11.01% |
| 2015 | $5.88B | +$3.24B | +122.61% |
| 2014 | $2.64B | $-231.50M | -8.05% |
| 2013 | $2.88B | +$700.00M | +32.18% |
| 2012 | $2.17B | +$89.50M | +4.29% |
| 2011 | $2.09B | +$258.80M | +14.17% |
| 2010 | $1.83B | +$849.50M | +86.93% |
| 2009 | $977.20M | $-623.30M | -38.94% |
| 2008 | $1.60B | +$523.00M | +48.54% |
| 2007 | $1.08B | +$474.50M | +78.69% |
| 2006 | $603.00M | $-1.50M | -0.25% |
| 2005 | $604.50M | $-284.80M | -32.03% |
| 2004 | $889.30M | +$533.00M | +149.59% |
| 2003 | $356.30M | $-159.70M | -30.95% |
| 2002 | $516.00M | +$13.20M | +2.63% |
| 2001 | $502.80M | +$149.10M | +42.15% |
| 2000 | $353.70M | $-129.10M | -26.74% |
| 1999 | $482.80M | $-92.70M | -16.11% |
| 1998 | $575.50M | $-114.10M | -16.55% |
| 1997 | $689.60M | $-572.00M | -45.34% |
| 1996 | $1.26B | — | — |
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter